Results 121 to 130 of about 35,256 (161)

Ofatumumab, a human anti-CD20 monoclonal antibody

Expert Opinion on Biological Therapy, 2010
Since relapse of chronic lymphocytic leukemia (CLL), and refractoriness to treatment following relapse, is inevitable after initial treatment, development of novel treatment strategies is necessary.CD20 as a therapeutic target for CLL, successes and limitations of current anti-CD20 monoclonal antibody (mAb) therapy, and implications of preclinical and ...
openaire   +2 more sources

Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis

CNS Drugs, 2020
Multiple sclerosis (MS) was previously thought to be a T-cell-mediated, demyelinating disease of the central nervous system. Disease-modifying therapies targeting T cells have, indeed, shown remarkable efficacy in patients with relapsing-remitting MS.
Finn Sellebjerg, Morten Blinkenberg, Per Soelberg Sorensen   +2 more
openaire   +3 more sources

Treatment of SLE with Anti-CD20 Monoclonal Antibody

2004
Systemic lupus erythemaotsus (SLE) is an autoimmune disease involving multiple organ systems and characterized by anti-nuclear antibodies. While T cells and dendritic cells may play major roles in SLE, several lines of evidence strongly suggest a central role for B cells.
R John, Looney, Jennifer, Anolik, Iñaki, Sanz   +2 more
openaire   +2 more sources

Treatment of Refractory Pemphigus with the Anti-CD20 Monoclonal Antibody (Rituximab)

Dermatology, 2007
<i>Background:</i> Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant ...
A.V. Marzano, D. Fanoni, L. Venegoni, E. Berti, R. Caputo   +4 more
openaire   +2 more sources

Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy

Journal of Clinical Oncology, 2023
openaire   +2 more sources

Anti-CD20-monoclonal-antibody/immune-globulin

Reactions Weekly, 2022
openaire   +1 more source

Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins

Nature Reviews Molecular Cell Biology, 2021
Ning Jia, Dinshaw J Patel
exaly  

Anti-CD20 monoclonal antibody/thalidomide

Reactions Weekly, 2001
openaire   +1 more source

Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?

Nature Reviews Clinical Oncology, 2021
Michael Karin
exaly  

Anti-obesity drug discovery: advances and challenges

Nature Reviews Drug Discovery, 2021
Timo D Müller, Matthias Blüher, Matthias Tschoep   +2 more
exaly